IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1843
Positioning
Market Dominance
Manufacturing
Medical Equipment
$566M
Devdatt Kurdikar
Embecta Corp. focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
Headcount
1.9K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = EMBC ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EMBC Embecta Corp. | 51 | 68 | 95 | 23 | 5.0x | 2.1x | -28.9% | 12.0% | 65.4% | 27.1% | 11.7% | -9.0% | 6.2% | - | $566M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Embecta Corp. (EMBC) receives a "Hold" rating with a composite score of 51.1/100. It ranks #1843 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
Pending Verification
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for EMBC.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 68 | 79 | -11DRAG |
| MOMENTUM | 23 | 11 | +12ALPHA |
| VALUATION | 95 | 98 | -3NEUTRAL |
| INVESTMENT | 42 | 78 | -36DRAG |
| STABILITY | 57 | 54 | +3NEUTRAL |
| SHORT INT | 33 | 24 | +9ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -28.9% (sector -1.9%)
GM 65% vs sector 44%, OM 27% vs sector 3%
Capital turnover N/A, R&D intensity 1.8%
Rev growth -9%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Embecta Corp. (EMBC) as a Hold with a composite score of 51.1/100 at a current price of $10.24. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Embecta Corp. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 51.1/100 places it at rank #1843 in our full universe.
No Moat
Low
Poor
Undervalued
Gross margins of 65% signal strong pricing power.
Value factor score of 95 suggests attractive pricing.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Embecta Corp. represents a hold based on multi-factor quantitative performance.
Our model assigns Embecta Corp. a Hold rating, with a composite score of 51.1/100 and 3 out of 5 stars. Ranked #1843 of 7,333 stocks, EMBC presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
EMBC earns a quality score of 68/100, indicating above-average business quality. The company reports a return on equity of -28.9% (sector avg: -1.9%), gross margins of 65.4% (sector avg: 44.1%), net margins of 11.7% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
From a valuation perspective, EMBC scores an exceptional 95/100, indicating the stock trades at a deep discount relative to its fundamentals. Key valuation metrics include a P/E ratio of 4.97x, an EV/EBITDA of 2.15x. A value score this high suggests the market may be significantly underpricing the company's earnings power, assets, or cash flow generation.
With an investment score of 42/100, EMBC exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of -9.0% vs. a sector average of 6.7% and a return on assets of 12.0% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
Embecta Corp. is experiencing notably weak momentum with a score of just 23/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -9.0% year-over-year, while a beta of 0.97 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 57/100, EMBC exhibits average financial resilience. Key stability metrics include a beta of 0.97. While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
Embecta Corp.'s short interest score of 33/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include small-cap liquidity risk. At $566M (small-cap), EMBC carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Embecta Corp. offers an attractive dividend yield of 6.2%, placing it among the higher-yielding stocks in its peer group. A yield this high can provide meaningful income, but investors should verify the payout is sustainable by examining the payout ratio, free cash flow coverage, and any history of dividend cuts.
Embecta Corp. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1843 of 7,333 overall (75th percentile). Key comparisons include ROE of -28.9% trailing the -1.9% sector median and operating margins of 27.1% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While EMBC currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (95) vs Momentum (23) — closing this gap could shift the rating.
EV/EBITDA 81% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 1422% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 49% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...
Despite posting healthy earnings, Embecta Corp.'s ( NASDAQ:EMBC ) stock has been quite weak. Our analysis suggests that...
PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the “Board”) of embecta has elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...